Juan Pablo T.
- Country
- Spain
- Department
- Neurology
Research Overview
- Phase II Evaluation of Dasatinib and Quercetin Senolytic Therapy in Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease
- Evaluation of the Efficacy and Safety of Xanomeline Tartrate and Trospium Chloride in Cognitive Impairment Associated with Mild to Moderate Alzheimer's Disease
- Efficacy and Safety Evaluation of MK-1167 as Adjunctive Therapy in Mild to Moderate Alzheimer's Disease Dementia: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 6 of 60 partner sites.
Specializations
Neurodegenerative Disease Research
The investigator specializes in innovative approaches to treating Alzheimer's Disease and mild cognitive impairment, with particular emphasis on memory-related cognitive disorders.
- Early-stage Alzheimer's Disease interventions
- Amnestic cognitive impairment therapeutics
- Memory disorder treatments
Their research explores novel therapeutic pathways in neurodegenerative conditions.
Cellular Biology Applications
The investigator focuses on senolytic therapy applications in neurodegenerative conditions, exploring cellular mechanisms of cognitive decline.
- Cellular senescence in neurodegeneration
- Blood biomarker analysis
- Tau protein pathology
Their work integrates cellular biology insights with therapeutic applications.
Therapeutic Innovation
The investigator develops novel therapeutic approaches using combined treatment modalities for neurodegenerative conditions.
- Novel drug combinations
- Disease progression modulation
- Cognitive function preservation
Their research explores innovative treatment strategies for cognitive disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.